Bo Han

Bo Han


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
WYWanli Yu
Wanli Yu
PWPengfei Wu
Pengfei Wu
FWFang Wang
Fang Wang
LMLi Miao
Li Miao
BHBo Han
Bo Han
ZJZhiqun Jiang
Zhiqun Jiang
Background: Glioblastoma multiforme (GBM) is characterized by widespread genetic and transcriptional heterogeneity. Aberrant DNA methylation plays a vital role in GBM progression by regulating gene expression. However, little is known about the role of methylation and its association with prognosis in GBM. Our aim was to explore DNA methylation-driven genes (DMDGs) and provide evidence for survival prediction and individualized treatment of GBM patients.Methods: Use of the MethylMix R package identified DMDGs in GBM. The prognostic signature of DMDGs based on the risk score was constructed by multivariate Cox regression analysis. Receiver operating characteristics (ROC) curve and C-index were applied to assess the predictive performance of the DMDG prognostic signature. The predictive ability of the multigene signature model was validated in TCGA and CGGA cohorts. Finally, the role of DMDG β-Parvin (PARVB) was explored in vitro.Results: The prognostic signature of DMDGs was constructed based on six genes (MDK, NMNAT3, PDPN, PARVB, SERPINB1, and UPP1). The low-risk cohort had significantly better survival than the high-risk cohort (p < 0.001). The area under the curve of the ROC of the six-gene signature was 0.832, 0.927, and 0.980 within 1, 2, and 3 years, respectively. The C-index of 0.704 indicated superior specificity and sensitivity. The six-gene model has been demonstrated to be an independent prognostic factor for GBM. In addition, joint survival analysis indicated that the MDK, NMNAT3, PARVB, SERPINB1, and UPP1 genes were significantly associated with prognosis and therapeutic targets for GBM. Importantly, our DMDG prognostic model was more suitable and accurate for low-grade gliomas. Finally, we verified that PARVB induced epithelial-mesenchymal transition partially through the JAK2/STAT3 pathway, which in turn promoted GBM cell proliferation, migration, and invasion.Conclusion: This study demonstrated the potential value of the prognostic signature of DMDGs and provided important bioinformatic and potential therapeutic target data to facilitate individualized treatment for GBM, and to elucidate the specific mechanism by which PARVB promotes GBM progression.

Verified
Journal Article
Open access
PDF file
YSYing Sun
Ying Sun
YTYu Tian
Yu Tian
GWGuang-Zhi Wang
Guang-Zhi Wang
ZHZhao Hong
Zhao Hong
BHBo Han
Bo Han
CJChuanlu Jiang
Chuanlu Jiang
Gliomas are malignant primary brain tumors with poor prognosis. Recently, research was indicative of a tight connection between tumor malignancy and genetic alterations. Here, we propose an oncogenic implication of transforming acidic coiled-coil-containing protein 3 (TACC3) in gliomas. By comprehensively analyzing the Chinese glioma genome atlas (CGGA) and publicly available data, we demonstrated that TACC3 were overexpressed along with glioma grade and served as an independent negative prognostic biomarker for glioma patients. Functions’ annotations and gene sets’ enrichment analysis suggested that TACC3 may participate in cell cycle, DNA repair, epithelium-mesenchymal transition and other tumor-related biological processes and molecular pathways. Patients with high TACC3 expression showed CD133+ stem cell properties, glioma plasticity and shorter overall survival time under chemo-/radio-therapy. Additionally, a TACC3 associated the miRNA-mRNA network was constructed based on in silico prediction and expression pattern, which provide a foundation for further detection of TACC3-miRNA-mRNA axis function. Collectively, our observations identify TACC3 as an oncogene of tumor malignancy, as well as a prognostic and motoring biomarker for glioma patients.

10 April 2025 in Chinese Medical Journal
Verified
Journal Article
Open access
YCYuanhao Chang
Yuanhao Chang
JYJingchen Yang
Jingchen Yang
ZLZhuo Li
Zhuo Li
XZXiaoxue Zhu
Xiaoxue Zhu
TJTao Jiang
Tao Jiang
XLXing Liu
Xing Liu
Background: Epidermal growth factor receptor variant III ( EGFRvIII ) mutation is the most prevalent genetic change in glioblastoma. Abnormal DNA damage repair caused by EGFRvIII, which leads to temozolomide (TMZ) resistance, is a major cause of reduced postoperative survival in glioblastoma patients. This study aims to uncover the molecular mechanism of TMZ resistance in EGFRvIII -mutant glioblastoma. Methods: We constructed a Clustered regularly interspaced shortpalindromic repeats (CRISPR)/CRISPR-associated (Cas) system 9 library to identify synthetic lethal genes for EGFRvIII -bearing cells. Abnormal epigenetic regulation of the RAD51-associated protein 1 ( RAD51AP1 ) promoter was assessed via chromatin immunoprecipitation sequencing (ChIP-seq) and chromatin immunoprecipitation polymerase chain reaction (ChIP-PCR) analyses. In vitro and in vivo experiments were carried out to investigate the role of the RAD51AP1 gene in TMZ resistance in EGFRvIII -bearing glioblastoma. Results: The CRISPR/Cas9 library identified RAD51AP1 , a synthetic lethal gene for EGFRvIII -bearing cells exposed to TMZ. ChIP-seq and ChIP-PCR analyses revealed that acetylated histone H3 lysine 27 (H3K27ac) and SRY-box transcription factor 9 ( SOX9 ) together induced RAD51AP1 transcription in EGFRvIII cells. High expression levels of RAD51AP1 , promoted formation of the RAD51–UAF1 complex to activate homologous recombination and inhibit TMZ-induced DNA damage. Conclusion: The results of this study suggest that aberrant RAD51AP1 expression is a crucial mechanism by which EGFRvIII -mutant glioblastoma resists TMZ chemotherapy, laying the groundwork for future personalized medicine.

26 December 2025 in Cancer Communications
Verified
Journal Article
Open access
JYJingchen Yang
Jingchen Yang
XLXuejing Li
Xuejing Li
XZXiaoxue Zhu
Xiaoxue Zhu
ZLZiwei Li
Ziwei Li
XCXiaoyong Chen
Xiaoyong Chen
XLXing Liu
Xing Liu
Background: Hypoxia is a prevalent, characteristic feature of the tumor microenvironment (TME) in glioblastomas (GBMs). As dominant immune cells within the TME, glioma-associated macrophages (GAMs) crucially regulate tumor progression. A comprehensive understanding of the effect of hypoxia on the behavior of GAMs is essential for elucidating the immune landscape and developing innovative therapeutic strategies. This study aimed to elucidate the mechanisms by which GAMs facilitate GBM progression under hypoxic conditions. Methods: Transcriptome sequencing, single-cell RNA sequencing, and spatial transcriptomic analyses were performed to explore the correlation between hypoxia and GAMs. Clinical samples were used to validate the findings. The underlying molecular mechanisms were examined via chromatin immunoprecipitation, quantitative real-time polymerase chain reaction, Western blotting analysis, and immunofluorescence assays. The therapeutic effectiveness was assessed via the use of in vivo models. Results: A subset of GAMs with elevated osteopontin (OPN) expression accumulates in response to hypoxic stimulation. Hypoxia induces OPN expression in macrophages via the histone 3 lysine 4 trimethylation–WD40 repeat-containing protein 5 (H3K4me3-WDR5) epigenetic axis. These OPN-positive GAMs (OPN+ GAMs) enhance the mesenchymal transition in GBMs by secreting OPN into the TME. Mechanistically, OPN activates nuclear factor κB (NF-κB) signaling through cluster of differentiation 44 (CD44), subsequently leading to increased programmed cell death ligand 1 (PD-L1) expression. The inhibition of OPN increased GBM sensitivity to temozolomide (TMZ) in orthotopic models. Conclusions: This study revealed the potential mechanism by which hypoxia-induced OPN+ GAMs promote the mesenchymal transition in GBM cells and demonstrated the therapeutic potential of targeting OPN to enhance TMZ treatment effectiveness.